Coherus BioSciences - Articles and news items

Investigational Enbrel biosimilar CHS-0214 meets primary endpoints

Industry news / 10 November 2015 / Victoria White

CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+